Cell Genesys CEO Stephen A. Sherwin, M.D made $1.3 million last year, with $577,500 coming from base salary. He did so well, in the eyes of the board, that his base was raised to $602,500. Who knows how well he will do with bonuses and perks.
CEGE blew up today. The company ended a clinical trial of its prostate cancer vaccine GVAX because patients who were treated with the vaccine were dying more frequently than those only given a standard treatment.
That bit of bad news took the shares down to $.69 from a 52-week high of $4.67.
The market cap of Cell Genesys is only $62 million now, so Dr. Sherwin is doing a bit too well.
Douglas A. McIntyre